metabolic syndome. Metabolic disorder, unspecified
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: protocol have three or more of the five listed:Abdominal obesity (waist circumference greater than or equal to 102 cm in men and greater than or equal to 88 cm in women)Low HDL-C levels (less than 40 mg / dL in men and less than 50 mg / dL in women)? High serum triglyceride level (mg / dL???=)? (high blood pressure (130/85 mmHg)) or under hypertension treatment5) impaired glucose homeostasis (110=F fasting blood glucose level)
Exclusion criteria
Exclusion criteria: Exclusion criteria include:A history of allergies and allergies to sunflower or seed or two or more types of nuts and seeds,Thyroid diseases (uncontrolled hyperthyroidism),Liver disease (obstruction or biliary disease), liver malformations,Alcoholism, smoking,Autoimmune diseases,Chronic pancreatitis,Kidney problems Nephritic syndrome or kidney disorders (increased blood creatinine more than 1.5 mg / dl),Digestive problems,Simultaneous presence in other clinical trials,Aspirin or any NSAID, propranolol, heparin, warfarin and antiplatelet use (such as Plavix)The presence of any infection or any infectious disease at the beginning or during the study, diabetic foot ulcer,Insulin, Multivitamins and Omega-3 supplements over the past 3 months, any steroids,High blood lipids or medications such as all types of blood lipid lowering agents (statins, gemfibrozil, niacin, lipase inhibitors) or physician discontinuation of blood lipid lowering drugs (at triglyceride levels less than 400 and LDL-C levels lower). Of 170)Hypoglycemic agents are not harmful if used during the past three months and continued during the study. Provided that the dose of the drug is not changed during the study.Also, people with a history of myocardial infarction or angioplasty or any non-outpatient surgery during the 6 months prior to the study,Pregnant and suspected pregnant or lactating women will not be allowed to enter the study.Exclusion criteria: These include: starting taking any of the above mentioned drugs and lipid lowering medications or changing the dosage of the drug, causing allergies or any discomfort with the intervention
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interleukin-6. Timepoint: At baseline (before intervention) and 7 weeks after flaxseed or sunflower oil consumption. Method of measurement: using ELIZA kit (IBL International GMBH, Germany).;Total antioxidant capacity. Timepoint: At baseline (before intervention) and 7 weeks after flaxseed or sunflower oil consumption. Method of measurement: using ELISA kit (ZellBio GMBH German).;Prothrombin Time. Timepoint: At baseline (before intervention) and 7 weeks after flaxseed or sunflower oil consumption. Method of measurement: The Prothrombin Time (PT) test was performed by adding the plasma to thromboplastin that converts prothrombin to thrombin. The mixture was then kept in a warm water bath at 37°C for one or two minutes. Afterwards, calcium chloride was added to the mixture and allow clotting to start. The test was timed from the addition of calcium chloride until the plasma clotted. This time was called PT.;Partial thromboplastin time. Timepoint: At baseline (before intervention) and 7 weeks after flaxseed or sunflower oil consumption. Method of measurement: In order to carry out Partial Thromboplastin Time (PTT) test, decalcified blood was used to prevent clotting before the test. At first, the plasma was separated via centrifugation. After that, ionized calcium and activating substances were added to the plasma. These substances included kaolin (hydrated aluminum silicate) and cephalin. The PTT refers to the time it takes for a clot to form, measured in seconds. | — |
Countries
Iran (Islamic Republic of)
Contacts
Shiraz University of Medical Sciences